ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The first test of Recursion's Exscientia move
The combined company's MALT1 inhibitor has started phase 1.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
ASCO 2025 – Braftovi breaks new ground
The Breakwater study hits on overall survival with "unprecedented" data.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
ASCO 2025 preview – patritumab hangs in the balance
Herthena-Lung02 data are an ASCO shocker.
